Literature DB >> 1350194

Inflammatory bowel disease presenting in pregnancy.

M R Morton1.   

Abstract

A case of inflammatory bowel disease (IBD) presenting in pregnancy is described. Despite previous reports of severe fulminating disease in this type of patient, this woman did well with an uncomplicated course; she responded to standard medical therapy and there were no fetal complications. IBD should not be a contraindication to pregnancy unless the disease is poorly controlled. Pregnancy does not increase the risk of relapse of IBD, but should this occur it is more likely in the first trimester or in the postpartum period. Treatment of IBD in pregnancy should be much the same as in the nonpregnant woman. Corticosteroids and sulphasalazine are safe in pregnancy and are the mainstays of medical treatment. Surgery should proceed for the usual indications of toxic megacolon and perforation. In the group requiring surgery fetal mortality is considerable but the maternal outcome is improving. Patients presenting with IBD in pregnancy may have more severe disease but recent reports suggest that the outcome for mother and infant in this group is improving.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1350194     DOI: 10.1111/j.1479-828x.1992.tb01896.x

Source DB:  PubMed          Journal:  Aust N Z J Obstet Gynaecol        ISSN: 0004-8666            Impact factor:   2.100


  2 in total

1.  Delivery of a normal newborn after intensive medical treatment for an acute exacerbation of ulcerative colitis during pregnancy: a case report.

Authors:  N Ishijima; E Ojima; H Tonouchi; H Suzuki; S Fukunishi
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 2.  Does lower gastrointestinal endoscopy during pregnancy pose a risk for mother and child? - a systematic review.

Authors:  Alison De Lima; Boris Galjart; Pieter H A Wisse; Wichor M Bramer; C Janneke van der Woude
Journal:  BMC Gastroenterol       Date:  2015-02-12       Impact factor: 3.067

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.